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Background: Several subsets of non–small-cell lung cancer (NSCLC) 
are defined by molecular alterations acting as tumor drivers, some 
of them being currently therapeutically actionable. The rat sarcoma 
(RAS)–rapidly accelerated fibrosarcoma (RAF)–mitogen-activated 
protein/extracellular signal-regulated kinase kinase (MEK)–extracel-
lular signal-regulated kinase (ERK) pathway constitutes an attractive 
potential target, as v-Raf murine sarcoma viral oncogene homolog B 
(BRAF) mutations occur in 2–4% of NSCLC adenocarcinoma.
Methods: Here, we review the latest clinical data on BRAF serine/
threonine kinase inhibitors in NSCLC.
Results: Treatment of V600E BRAF-mutated NSCLC with BRAF 
inhibitor monotherapy demonstrated encouraging antitumor activity. 
Combination of BRAF and MEK inhibitors using dabrafenib and tra-
metinib is under evaluation. Preliminary data suggest superior effi-
cacy compared with BRAF inhibitor monotherapy.
Conclusion: Targeting BRAF alterations represents a promising new 
therapeutic approach for a restricted subset of oncogene-addicted 
NSCLC. Prospect ive trials refining this strategy are ongoing. A next 
step will probably aim at combining BRAF inhibitors and immu-
notherapy or alternatively improve a multilevel mitogen-activated 
protein kinase (MAPK) pathway blockade by combining with ERK 
inhibitors.
Key Words: BRAF, V600E, MEK, Vemurafenib, Dabrafenib, 
Trametinib, Non–small-cell lung cancer.
(J Thorac Oncol. 2015;10: 1396–1403)
Lung cancer is a leading cause of cancer death worldwide,1,2 with 1.6 million deaths annually. Environmental factors 
and genetic alterations seem to contribute to increase lung 
cancer risk.3–6 Although the majority of lung cancer cases is 
related to tobacco smoking,7 10–30% occurs in light-smoker or 
never-smoker patients, with a higher proportion of light-smoker 
or never-smokers in Asian countries.8 Therapeutic decisions 
have traditionally been based on tumor histology. Non–small-
cell lung cancer (NSCLC) accounts for 85% to 90% of lung 
cancers, with over 60% diagnosed at an advanced stage.9 
Advanced NSCLC is usually treated with platinum-based dou-
blet chemotherapy, with inevitable subsequent relapse.
In NSCLC, numerous molecular alterations have been 
recently reported and defined as driver oncogenes following 
their role in transforming and maintaining cancer cells in 
preclinical models, such as epidermal growth factor receptor 
(EGFR), human epidermal growth factor receptor 2 (HER2), 
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
(KRAS), v-Raf murine sarcoma viral oncogene homolog B 
(BRAF), MNNG HOS transforming gene (MET) and phos-
phatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
alpha (PIK3CA) mutations, anaplastic lymphoma kinase 
(ALK), v-ros avian UR2 sarcoma virus oncogene homolog 
1 (ROS1) and rearranged during transfection (RET) chromo-
somal rearrangements, and PIK3CA, MET, and HER2 ampli-
fications. Most molecular aberrations seem to occur mainly 
in adenocarcinoma and are more frequently encountered in 
never smokers.5,6,10,11 These mutations offer promising new 
therapeutic approaches, and the use of specific targeted agents 
has changed the landscape of lung cancer treatment. Agents 
targeting the abnormal activity of EGFR and ALK kinases 
have been validated as first-line treatment for advanced 
NSCLC harboring theses molecular alterations, with a bet-
ter overall response rate (ORR) and progression-free survival 
(PFS) compared with standard chemotherapy.12–16
BRAF Mutations
The rat sarcoma (RAS)–rapidly accelerated fibrosarcoma 
(RAF)–mitogen-activated protein/extracellular signal-regulated 
kinase kinase (MEK)–extracellular signal-regulated kinase 
(ERK) mitogen-activated protein kinase pathway is one of the 
most important canonical cancer signaling pathways, mediat-
ing cellular responses to growth signals essential for cell prolif-
eration and survival (Fig. 1).17,18 Its role in carcinogenesis was 
initially proposed based on its frequent dysregulation in human 
cancer. BRAF is a member of the serine/threonine kinase RAF 
family (including the isoforms v-Raf murine sarcoma viral 
oncogene homolog A  [ARAF], BRAF, v-Raf murine sarcoma 
viral oncogene homolog C [CRAF]) that is regulated by bind-
ing to RAS and directly activating MEK1/2, which can further 
phosphorylate ERK1/2. RAS and BRAF oncogenic mutations 
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are usually mutually exclusive events.5,10,19 BRAF is mutated in 
8% of all human cancers, predominately in hairy cell leukemia 
(100%), melanoma (50%), papillary thyroid carcinoma (45%), 
colorectal (10%), and rarely in ovarian and lung cancer.5,10,19 
Almost all nonsynonymous activating and nonactivating BRAF 
mutations have been identified in exon 11 and exon 15.19–21 A 
T1799 point mutation in exon 15 of the BRAF gene, resulting in 
a valine to glutamate substitution at codon 600 (V600E) affect-
ing the kinase domain of the BRAF protein, is the most com-
mon oncogenic driver mutation in melanoma (90%).19,22
The BRAF V600E mutation results in constitutive acti-
vation of its serine/threonine kinase, with a high dependency 
on downstream MEK signaling, and represents an actionable 
component of this pathway.23,24 BRAF inhibitors have been 
FIGURE 1.  Illustration of RAS–RAF–MEK–ERK MAP kinase signaling pathway. Current inhibitors targeting BRAF, MEK, and ERK 
are depicted. AKT, Ak strain transforming; ARAF, v-Raf murine sarcoma viral oncogene homolog A; BRAF, v-Raf murine sarcoma 
viral oncogene homolog B; CRAF, v-Raf murine sarcoma viral oncogene homolog C; ERK-1/2, extracellular signal-regulated 
kinase 1/2; GDP, guanosine diphosphate; GRB2, growth factor receptor-bound protein 2; GTP, guanosine triphosphate; MAP, 
mitogen-activated protein; MEK1/2, mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2; mTOR, mam-
malian target of rapamycin; P, phosphate; PI3K, phosphatidylinositol 3-kinase; PLCγ, phospholipase Cγ; RAF, rapidly accelerated 
fibrosarcoma; RAS, rat sarcoma; RHEB, Ras homolog enriched in brain; RTK, receptor tyrosine kinase; SHC, Src homology 2 
domain-containing-transforming protein; SOS, son of sevenless; TSC1/2, tuberous sclerosis protein 1/2.
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extensively studied in melanoma, where vemurafenib and dab-
rafenib have been approved (in 2011 and 2013, respectively) 
as single agents for the treatment of patients with advanced 
melanoma with BRAF V600E mutation.25–27 Vemurafenib and 
dabrafenib are type I BRAF serine/threonine kinase inhibitors 
that have higher selectivity for BRAF V600E mutant protein 
than wild-type BRAF,28,29 with essentially no activity against 
other human kinases. They preferentially bind the active site 
of the serine/threonine kinase domain of BRAF, which is con-
stitutively activated in V600E mutants, in contrast to type II 
BRAF inhibitors such as sorafenib, which preferentially bind 
the inactive conformation. They are very potent against preclin-
ical BRAF V600E mutants, with a half maximum inhibitory 
concentration (IC
50
) of 31 nM for vemurafenib and 0.65 nM 
for dabrafenib. The MEK inhibitor trametinib has also been 
approved (in 2013) as monotherapy for patients with advanced 
melanoma with either a BRAF V600E or V600K mutation.30 
Trametinib is a MEK1/2 inhibitor with a favorable pharma-
cokinetic profile and a long circulating half-life. The drug 
inhibits MEK1/2 kinase activity and prevents RAF-dependent 
MEK phosphorylation.18,31 Recently, the combination of dab-
rafenib and trametinib has shown superior efficacy compared 
with BRAF inhibitor monotherapy in BRAF V600E-mutated 
or V600K-mutated advanced melanomas,32–35 hence becoming 
the new standard therapy for this indication.
BRAF Mutations in Lung Cancer
BRAF mutations are detected in approximately 2% to 
4% of lung cancer, hence occurring at a lower frequency than 
EGFR mutations (10–15%) and probably in a slightly smaller 
subpopulation than ALK rearrangements (3–5%). These 
mutations have been predominantly diagnosed in the adeno-
carcinoma histological subtype, without obvious ethnicity or 
gender predominance.5,19 Preclinical data in mice suggested 
a potential oncogenic role of BRAF mutations in the devel-
opment of lung adenocarcinoma.36 In contrast to melanoma 
where V600 mutations represent the vast majority of encoun-
tered BRAF mutations, V600E mutations represent only about 
half of BRAF mutations detected in NSCLC. Although V600E 
mutations are related to an elevated basal kinase activity com-
pared with wild-type BRAF, non-V600E BRAF mutations 
occur often in the phosphate-binding loop (P-loop), which is 
the adenosine triphosphate (ATP) binding site.19
TABLE 1.  Clinical Features and Outcome of BRAF-Mutated NSCLC Patients
First author Paik20 Marchetti37 Ilie38 Cardarella39 Luk21 Litvak40 Brustugun41 Villaruz42
Country United States Italy France United States Australia United States Norway United States
Year 2011 2011 2013 2013 2014 2014 2014 2015
Patients (n) 697 1046 450 883 273 63 979 951
BRAF (n) 18 (2.6%) 37 (3.5%) 40 (8.9%) 36 (4.1%) 7 (2.6%) 63 (NA) 17 (1.7%) 21 (2.2%)
V600E (%) 50 57 52 50 57 57 NA (100) 81
Smokers (%)
  V600E 100 52a 57 72 100 57 71 76
  Non-V600E 100 100a 89 89 100 43 NA 100
Female (%)
  V600E 78 76a 52 56 75 53 59 53
  Non-V600E 44 7a 26 50 33 56 NA 25
V600E (n)
  Early stage (I and II) 3 (33%)b 11 (52%)a 6 (29%) 3 (17%) NA 11 (31%) 6 (35%) 5 (31%)c
  Advanced stage (III and IV) 6 (67%)b 10 (48%)a 15 (71%) 15 (83%) NA 25 (69%) 11 (65%) 11 (69%)c
Non-V600E (n)
  Early stage (I and II) 5 (56%)b 12 (80%)a 8 (42%) 2 (11%) NA 10 (37%) NA 1 (25%)
  Advanced stage (III and IV) 4 (44%)b 3 (20%)a 11 (58%) 16 (89%) NA 17 (63%) NA 3 (75%)
Survival outcomed
  BRAF mutant vs. wt Samee Same NA Same NA Samef NA Sameg
  V600E vs. wt NA Worse NA NA NA NA Same NA
  Non-V600E vs. wt NA Same NA NA NA NA NA NA
  V600E vs. non-V600E NA Worse Worse Sameh NA Betteri NA NA
aThe clinical features of one patient with non-V600E-mutated squamous cell carcinoma were not reported by Marchetti et al37 and were note taken into account in this table.
bPaik et al20 defined early stage as I to IIIA and advanced stage as IIIB to IV.
cThe staging of one patient with BRAF V600E mutant was not reported by Villaruz et al42 and was not taken into account in this table.
dSurvival outcome and comparison between studies have to be taken with precaution, as the analyses were conducted over small numbers and different tumor stages.
eOS was calculated for advanced stage BRAF mutants versus other driver mutations (EGFR, KRAS, and ALK).
fOS was compared for early and advanced BRAF mutants versus KRAS or EFGR mutations.
gOS was compared between BRAF mutants and other driver mutants (EGFR, KRAS, ALK) or wild-type.
hNot statistically significant.
iBetter OS was found with advanced IIIB to IV stage BRAF V600E mutants, but OS was the same in early I to IIIA stage between V600E and non-V600E mutants.
BRAF, v-Raf murine sarcoma viral oncogene homolog B; NSCLC, non–small-cell lung cancer; NA, not applicable; V600E, valine to glutamate substitution at codon 600; OS, 
overall survival; wt, wild-type; EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ALK, anaplastic lymphoma kinase.
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The biological and prognostic impact of BRAF mutations 
in NSCLC have been reported in several retrospective stud-
ies, all limited by the small patient numbers (Table 120,21,37–42). 
The prognostic impact of V600E and non-V600E mutations 
remain contradictory in the reported series available.37,40 Paik 
et al20 performed an institutional analysis at Memorial Sloan-
Kettering Cancer Center on 697 consecutive early-stage and 
late-stage lung adenocarcinoma. BRAF mutations occurred 
in 3% of patients, and the mutations identified were V600E 
(50%), G469A, and D594G. All patients were current or former 
smokers, and there was no difference in overall survival (OS) 
for BRAF-mutated patients when compared with other EGFR-
mutated, ALK-mutated, or KRAS-mutated subpopulations.
Marchetti et al37 reported the results of a retrospec-
tive series of 1046 surgically resected NSCLC (squamous and 
nonsquamous cell) patients. BRAF mutations were found in 
3.5% of the tumors and in 4.9% of lung adenocarcinoma. The 
V600E mutation occurred in 2.8% of adenocarcinoma, more 
often among never-smokers, females, and aggressive histologi-
cal types (micropapillary) and represented 58% of all BRAF 
mutations documented. Patients with the BRAF V600E mutation 
had shorter disease-free survival (DFS) and OS compared with 
wild-type and non-V600E mutations. In contrast, non-V600E 
mutations were found in current or former smokers. There was 
no difference in disease-free survival or OS observed in patients 
with or without non-V600E mutations. In this analysis, all BRAF-
mutated tumors were found to be KRAS negative. Luk et al21 
conducted a mutation analysis for BRAF, EGFR, and KRAS in 
273 advanced NSCLC patients and found that BRAF mutations 
occurred in 2.6% of cases. All patients had a smoking history in 
contrast to the EGFR-mutated population, and there was no dif-
ference in sex distribution between BRAF mutant and wild-type 
patients. The V600E mutation accounted in 58% of patients and 
was associated with the aggressive micropapillary subtype.
According to Cardarella et al,39 BRAF mutations were 
identified in 4% of lung adenocarcinoma in a retrospective 
analysis of 883 patients with NSCLC, half of whom had V600E 
mutations. There were no differences in clinical features between 
BRAF-mutated and wild-type patients. However, the analysis 
suggested that patients with the V600E mutation seem to have 
shorter PFS after platinum-based chemotherapy. Recently, the 
Lung Cancer Mutation Consortium reported on a series of 63 
patients with BRAF mutations in advanced stage adenocarci-
noma and found a high incidence of V600E mutations (80%).42 
BRAF mutations were more likely to occur in current or former 
smokers with no gender predominance. There was no difference 
in OS between BRAF mutant and wild-type patients.
Therapy of BRAF Mutant NSCLC
In vitro preclinical models of NSCLC demonstrated 
that both vemurafenib and trametinib were effective as single 
agents in BRAF V600E mutant cells.43 Moreover, trametinib 
was also effective in non-V600E mutants. The combination 
of vemurafenib and trametinib increased tumor cell death, 
suggesting that the combination should be more effective.43 
Two other MEK inhibitors (PD0325901 and CI-1040) have 
also shown activity in in vitro and in vivo preclinical models 
of NSCLC with BRAF V600E or non-V600E mutations.44–46
In patients with NSCLC harboring the BRAF V600E 
mutation, partial responses (PR) or complete responses (CR) 
have been reported for vemurafenib47–50 and dabrafenib mono-
therapies.51–53 However, the responses were not durable.49,50,52 
Sorafenib has also been reported to be active in patients with 
BRAF mutant NSCLC.54 An update from the European EURAF 
cohort study was presented at the European Lung Cancer 
Conference 2015.55 This retrospective multicenter study col-
lected data from patients with advanced NSCLC with BRAF 
mutations, who were treated with at least one BRAF inhibitor 
outside of a dedicated clinical trial. Out of 35 patients, all with 
adenocarcinoma, 83% had BRAF V600E mutations, and 17% 
had non-V600E mutations (such as G466V, G469A, G469L, 
G596V, V600K, and K601E). Seventy-four percent patients 
received vemurafenib, 23% dabrafenib, and 3% sorafenib. 
Most patients received one line of BRAF inhibitors, whereas 
11% patients received two lines of BRAF inhibitors. Although 
most BRAF inhibitors (86%) were used after at least one line 
of chemotherapy, five patients received BRAF inhibitors as first 
line, among who three achieved a PR. ORR was 53%, with 85% 
disease control rate (DCR), including 6% CR, 47% PR, and 
32% stable disease. The planned subgroup analysis of BRAF 
V600E patients receiving vemurafenib showed 54% ORR and 
96% DCR. PFS with first-line therapy (including chemother-
apy) was 9.3 months for V600E and 1.5 months for non-V600E, 
and OS was 25.2 and 11.8 months, respectively. Overall, PFS 
and OS using a BRAF inhibitor for V600E mutants were 5 and 
10.8 months, respectively. The duration of BRAF therapy was 
4.3 months, ranging from 0.5 to 41 months, with some patients 
having durable responses. Most patients with non-V600E muta-
tions did not respond to BRAF inhibitors and had a significantly 
poorer outcome, although CR was observed with one BRAF 
G596V-mutated NSCLC patient treated with vemurafenib. The 
mechanism of non-V600E BRAF-mutated NSCLC primary 
resistance to BRAF inhibitors is not fully understood. Three-
dimension structural modeling of BRAF G469L suggested that 
it induces a conformational change impairing the binding of 
vemurafenib and dabrafenib.56
Prospective Studies
There are very few completed or ongoing prospec-
tive clinical trials in BRAF-mutated NSCLC, undoubtedly 
related to the rarity of these alterations and subsequent dif-
ficulty in enrolling and randomizing these patients. The 
multicenter VE-BASKET (NCT01524978) phase II study is 
assessing vemurafenib in BRAF V600-mutated nonmelanoma 
solid tumors, including NSCLC.57 Out of 19 patients with 
NSCLC, 42% had unconfirmed PR and 42% had stable dis-
ease. The study is still recruiting. AcSé (NCT02304809) is a 
French phase II study evaluating vemurafenib monotherapy 
in patients with BRAF V600-mutated nonmelanoma solid 
tumors, including NSCLC. Results are pending.
The interim results of the BRF113928 (NCT01336634) 
prospective study was recently presented at the 2015 American 
Society of Clinical Oncology annual meeting.58 This mul-
ticenter, single-arm, two-stage, open-label phase II study 
assessed the safety and efficacy of dabrafenib and trametinib 
in patients with stage IV NSCLC with BRAF V600E mutation, 
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after failure of at least one line of chemotherapy. The first stage 
of the study evaluated the safety of dabrafenib as monother-
apy.53 In 78 patients who received at least one prior line of treat-
ment, ORR was 32%, DCR for more than 3 months was 56%, 
duration of response was 11.8 months, and 48% of responders 
had progressive disease. Among the six patients who received 
dabrafenib as first-line treatment, three achieved a PR. The 
most common adverse events (AEs) were similar to dabrafenib 
treatment in melanoma. Serious AEs occurred in 45%, with one 
death from intracranial hemorrhage. The second stage of the 
study evaluated the safety and efficacy of dabrafenib combined 
with trametinib.58 Out of 33 treated patients, 82% remained on 
therapy at the time of the interim analysis, 12% had progres-
sive disease, and 6% stopped because of AEs. Out of 24 evalu-
able patients, ORR was 63%, and DCR for more than 3 months 
was 88%, suggesting a superior antitumor activity than dab-
rafenib monotherapy. Toxicities were manageable and similar 
to those seen in previous studies in melanoma. Since the study 
passed the futility interim analyses, recruitment is ongoing. A 
third cohort assessing the combination treatment in previously 
untreated BRAF V600E NSCLC is currently recruiting.
A novel BRAF inhibitor LGX818 is currently being 
evaluated as monotherapy in an open-label, multicenter, 
single-arm phase II study in BRAF V600-mutated advanced 
NSCLC (NCT02109653). LGX818 is also being evaluated 
either in combination with the MEK inhibitor MEK162 or 
as a triplet combination with MEK162 and the cyclin-depen-
dent kinase inhibitor LEE011 in an open-label, multicenter, 
phase Ib/II study in BRAF-mutated advanced solid tumors 
(NCT01543698). Other interesting ongoing studies are the 
phase Ib/II studies assessing the phosphatidylinositol 3-kinase 
(PI3K) inhibitor BKM120 either in combination with tra-
metinib (NCT01155453) or the MEK inhibitor MEK162 
(NCT01363232) in selected advanced solid tumors, includ-
ing BRAF-mutated NSCLC. The MEK inhibitor selumetinib 
is also being assessed in a phase II study in nonmelanoma 
tumors with BRAF mutations (NCT00888134).
DISCUSSION
BRAF mutations represent rare driver alterations found in 
lung adenocarcinoma. Beyond this histological subtype, there is 
to date no clear clinical or pathological parameter that correlates 
with a higher prevalence of BRAF mutations. These mutations 
have been reported in heavy smokers, regardless of ethnicity 
and gender. The prognostic impact of BRAF mutations remains 
unclear to date, limited by the small numbers studied, with some 
series suggesting a worse outcome in this patient population.
Single-agent BRAF inhibitor therapy demonstrates 
activity in NSCLC; however, this activity is inferior to previ-
ous observations using ALK or EGFR tyrosine kinase inhibi-
tors (TKIs) in related oncogene-addicted NSCLC. It appears 
that the type of BRAF mutation observed is predictive of 
response to BRAF inhibitor therapy, with V600E mutations 
presenting with higher response rates and PFS. However, the 
numbers of non-V600E mutations treated prospectively is still 
very low, and no conclusion can be drawn yet. Furthermore, 
some specific non-600E mutations might confer sensitivity 
to BRAF inhibitors, such as G596V mutation.56 Of interest, 
a complete response was achieved with the TKI dasatinib in 
a unique case of NSCLC harboring BRAF Y472C.59 Further 
characterization of non-V600E mutations is required.
Importantly, all patients treated with BRAF inhibitors will 
eventually demonstrate tumor progression. Resistance mecha-
nisms to BRAF inhibitors are being thoroughly characterized 
in melanoma and consist of elevated expression of the kinases 
CRAF, COT or mutant BRAF, activating mutations in neuroblas-
toma RAS viral (v-ras) oncogene homolog (NRAS), MEK1 or 
Ak strain AKT1, aberrant splicing of BRAF, activation of PI3K 
through the loss of phosphatase and tensin homolog (PTEN), 
and persistent activation of receptor tyrosine kinases, including 
platelet-derived growth factor receptor β (PDGFRβ), insulin-
like growth factor 1 receptor (IGF-1R), and EGFR.60–66 However, 
resistance mechanisms to BRAF inhibitors in NSCLC have not 
been characterized yet. In a single case of BRAF V600E-mutated 
NSCLC treated with dabrafenib, molecular profiling revealed 
three new acquired mutations in KRAS, TP53, and CDKN2A.52 
This highlights the need to conduct serial biopsies and molecu-
lar profiling at baseline and at progression to gain insight into 
BRAF inhibitor resistance mechanisms.
A combination of BRAF and MEK inhibitors may delay 
the time to resistance/progression, similar to the situation in 
preclinical models and in melanoma. The dabrafenib and tra-
metinib combination in BRAF V600E-mutated NSCLC dem-
onstrated very promising response rates that surpass those of 
dabrafenib monotherapy, with safety profiles similar to those 
found in melanoma. Results from the combination of LGX818 
and MEK162 are awaited.
Future Strategies for BRAF-Mutated NSCLC
BRAF mutations have been identified in a variety of 
cancers, including NSCLC. Identifying the mechanisms of 
resistance to BRAF inhibitors in BRAF-mutated NSCLC will 
undoubtedly help in refining treatment strategies in the future. 
Moreover, it will guide strategies for front-line RAF targeted 
treatment or treatment at resistance. The role of dual BRAF/
MEK inhibition could also be better defined. Some mechanisms 
of resistance reported in melanoma may be relevant in NSCLC. 
Recently, mechanisms of resistance to combined BRAF/MEK 
inhibition in melanoma have also been proposed.67–69 These com-
prise BRAF alterations, BRAF amplifications, MEK mutations, 
PI3K–AKT–mammalian target of rapamycin (mTOR) pathway 
alterations, PTEN loss, cell cycle protein alteration, and NRAS 
mutations. One strategy to circumvent resistance to BRAF/
MEK inhibitors is to combine other pathway inhibitors, such as 
PI3K–AKT–mTOR inhibitors,70 ERK inhibitors,69–71 or CDK4/
CDK6 inhibitors. Tumor biopsies and analysis at progression is 
going to be necessary for full elucidation of resistance mecha-
nisms. This will allow for the development of rational, evidence-
based strategies for the next generation of clinical trials.
Non-V600E mutations should be better characterized 
in NSCLC to find appropriate agents for therapy. A better 
description of the genomic landscape of such tumors would 
be of great interest. Interestingly, some non-V600E muta-
tions seem to have variable degrees of kinase activity and 
might even confer resistance to BRAF inhibitors but are pos-
sibly sensitive to MEK inhibitors through transactivation of 
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CRAF.23 Thus, combinations of BRAF with MEK inhibitors 
should also be a potential option in this scenario.
Recently, with the emergence of immunotherapy and 
the recently reported striking benefit of checkpoint inhibitors 
in unselected patients with NSCLC in second-line therapy 
when compared with chemotherapy,72–76 more treatments can 
be offered to patients, and the opportunity for drug combina-
tions as well as the sequence of different compounds become 
a field of debate. Obviously, the right sequence of treatment—
including chemotherapy, targeted agents and immunother-
apy—should be rigorously tested in clinical trials.
Combining BRAF and/or MEK inhibitors and immu-
notherapy is tempting, and clinical trials testing these 
combinations are ongoing in melanoma but not in NSCLC 
yet. In favor of this strategy, recent studies demonstrated 
that high loads of mutations and tumor heterogeneity can 
increase the chance of benefiting from anti-CTLA-4 or pro-
grammed cell death protein 1 (PD-1) immunotherapy by 
generating tumor neoepitopes that are used as neoantigens 
and bind to major histocompatibility complex (MHC) class 
I molecules with great affinity.77–80 A higher mutational 
load has been reported in patients with a smoking history,81 
and BRAF mutations are often found in smokers. In addi-
tion, there are several small series suggesting tolerability 
and promising activity of combining TKIs and checkpoint 
inhibitors in NSCLC, suggesting that the combination of 
BRAF/MEK inhibitors with immunotherapy merits further 
research. As a direct consequence, BRAF-mutated patients 
should not be excluded from immunotherapy treatment 
strategies.
CONCLUSION
The landscape of NSCLC treatment has dramatically 
changed since the emergence of targeted agents against action-
able driver mutations, among which BRAF mutations belong. 
With immunotherapy soon becoming standard treatment after 
platinum-based chemotherapy, the complexity and diversity 
of treatment options is broadening. Finding the right personal-
ized biology-driven treatment for each patient at baseline and 
at recurrence is the quest for the next years to come.
There is a strong need to better characterize resistance 
mechanisms and validate predictive and prognostic biomark-
ers that will help treatment decision. To this end, molecular 
profiling of tumors at diagnosis and at subsequent relapse 
is crucial. The ability to molecularly characterize tumors 
through the use of circulating tumor cells or tumor DNA (so 
called liquid biopsies) will be a significant advance. It appears 
that this approach may indeed be feasible.82,83
Although such questions will always remain restricted 
to relatively small clinical trials, an international collaborative 
effort will be needed to accurately define standards of care in 
BRAF-mutated NSCLC and allow for the registration of new 
treatment options for this tiny patient population.
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